[Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].
Identifieur interne : 000056 ( Main/Exploration ); précédent : 000055; suivant : 000057[Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].
Auteurs : W. Huang [République populaire de Chine] ; T. Li [République populaire de Chine] ; Y. Ling [République populaire de Chine] ; Z P Qian [République populaire de Chine] ; Y Y Zhang [République populaire de Chine] ; D. Huang [République populaire de Chine] ; S B Xu [République populaire de Chine] ; X H Liu [République populaire de Chine] ; L. Xia [République populaire de Chine] ; Y. Yang [République populaire de Chine] ; S H Lu [République populaire de Chine] ; H Z Lu [République populaire de Chine]Source :
- Zhonghua nei ke za zhi [ 0578-1426 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Antagonistes des récepteurs aux angiotensines (MeSH), Betacoronavirus (MeSH), Chine (MeSH), Humains (MeSH), Hypertension artérielle (complications), Infections à coronavirus (complications), Inhibiteurs de l'enzyme de conversion de l'angiotensine (MeSH), Pandémies (MeSH), Pneumopathie virale (complications), Sujet âgé (MeSH), Études rétrospectives (MeSH).
- MESH :
- Wicri :
- geographic : République populaire de Chine.
English descriptors
- KwdEn :
- Aged (MeSH), Angiotensin Receptor Antagonists (MeSH), Angiotensin-Converting Enzyme Inhibitors (MeSH), Betacoronavirus (MeSH), China (MeSH), Coronavirus Infections (complications), Humans (MeSH), Hypertension (complications), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Retrospective Studies (MeSH).
- MESH :
- chemical : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors.
- geographic : China.
- complications : Coronavirus Infections, Hypertension, Pneumonia, Viral.
- Aged, Betacoronavirus, Humans, Middle Aged, Pandemics, Retrospective Studies.
Abstract
Objective: To analyze the effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) on coronavirus disease 2019 (COVID-19) patients with hypertension, and to provide an evidence for selecting antihypertensive drugs in those patients. Methods: Clinical data were retrospectively analyzed in 58 COVID-19 patients with hypertension admitted to Shanghai Public Health Clinical Center from January 20 to February 22, 2020, including epidemiological history, clinical manifestations, laboratory findings, chest CT and outcome. Patients were divided into ACEI/ARB group and non-ACEI/ARB group. Results: Twenty-six patients were in ACEI/ARB group and the other 32 patients in non-ACEI/ARB group, with median age 64.0 (49.5, 72.0) years and 64.0 (57.0, 68.8) years respectively. The median time to onset was 5(3, 8) days in ACEI/ARB group and 4 (3, 7) days in non-ACEI/ARB group, the proportion of patients with severe or critical illness was 19.2% and 15.6% respectively. The main clinical symptoms in two groups were fever (80.8% vs. 84.4%) and cough (23.1% vs. 31.3%). The following parameters were comparable including lymphocyte counts, C-reactive protein, lactate dehydrogenase, D-dimer, bilateral involvement in chest CT (76.9% vs. 71.9%), worsening of COVID-19 (15.4% vs. 9.4%), favorable outcome (92.3% vs. 96.9%) between ACEI/ARB group and non-ACEI/ARB group respectively (all P>0.05). However, compared with non-ACEI/ARB group, serum creatinine [80.49 (68.72, 95.30) μmol/L vs. 71.29 (50.98, 76.98) μmol/L, P=0.007] was higher significantly in ACEI/ARB group. Conclusions: ACEI/ARB drugs have no significant effects on baseline clinical parameters (serum creatine and myoglobin excluded) , outcome, and prognosis of COVID-19 patients with hypertension. Antihypertensive drugs are not suggested to adjust in those patients, but the potential impairment of renal function as elevation of serum creatinine should be paid attention in patients administrating ACEI/ARB drugs.
DOI: 10.3760/cma.j.cn112138-20200229-00155
PubMed: 32838499
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].</title><author><name sortKey="Huang, W" sort="Huang, W" uniqKey="Huang W" first="W" last="Huang">W. Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Li, T" sort="Li, T" uniqKey="Li T" first="T" last="Li">T. Li</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Ling, Y" sort="Ling, Y" uniqKey="Ling Y" first="Y" last="Ling">Y. Ling</name><affiliation wicri:level="1"><nlm:affiliation>Deparment of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Deparment of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Qian, Z P" sort="Qian, Z P" uniqKey="Qian Z" first="Z P" last="Qian">Z P Qian</name><affiliation wicri:level="1"><nlm:affiliation>Department of Severe Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Severe Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Y Y" sort="Zhang, Y Y" uniqKey="Zhang Y" first="Y Y" last="Zhang">Y Y Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Severe Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Severe Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Huang, D" sort="Huang, D" uniqKey="Huang D" first="D" last="Huang">D. Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hepatobiliary Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Hepatobiliary Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Xu, S B" sort="Xu, S B" uniqKey="Xu S" first="S B" last="Xu">S B Xu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Liu, X H" sort="Liu, X H" uniqKey="Liu X" first="X H" last="Liu">X H Liu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Xia, L" sort="Xia, L" uniqKey="Xia L" first="L" last="Xia">L. Xia</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Yang, Y" sort="Yang, Y" uniqKey="Yang Y" first="Y" last="Yang">Y. Yang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Lu, S H" sort="Lu, S H" uniqKey="Lu S" first="S H" last="Lu">S H Lu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Lu, H Z" sort="Lu, H Z" uniqKey="Lu H" first="H Z" last="Lu">H Z Lu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32838499</idno><idno type="pmid">32838499</idno><idno type="doi">10.3760/cma.j.cn112138-20200229-00155</idno><idno type="wicri:Area/Main/Corpus">000506</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000506</idno><idno type="wicri:Area/Main/Curation">000506</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000506</idno><idno type="wicri:Area/Main/Exploration">000506</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].</title><author><name sortKey="Huang, W" sort="Huang, W" uniqKey="Huang W" first="W" last="Huang">W. Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Li, T" sort="Li, T" uniqKey="Li T" first="T" last="Li">T. Li</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Ling, Y" sort="Ling, Y" uniqKey="Ling Y" first="Y" last="Ling">Y. Ling</name><affiliation wicri:level="1"><nlm:affiliation>Deparment of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Deparment of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Qian, Z P" sort="Qian, Z P" uniqKey="Qian Z" first="Z P" last="Qian">Z P Qian</name><affiliation wicri:level="1"><nlm:affiliation>Department of Severe Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Severe Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Y Y" sort="Zhang, Y Y" uniqKey="Zhang Y" first="Y Y" last="Zhang">Y Y Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Severe Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Severe Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Huang, D" sort="Huang, D" uniqKey="Huang D" first="D" last="Huang">D. Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hepatobiliary Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Hepatobiliary Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Xu, S B" sort="Xu, S B" uniqKey="Xu S" first="S B" last="Xu">S B Xu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Liu, X H" sort="Liu, X H" uniqKey="Liu X" first="X H" last="Liu">X H Liu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Xia, L" sort="Xia, L" uniqKey="Xia L" first="L" last="Xia">L. Xia</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Yang, Y" sort="Yang, Y" uniqKey="Yang Y" first="Y" last="Yang">Y. Yang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Lu, S H" sort="Lu, S H" uniqKey="Lu S" first="S H" last="Lu">S H Lu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author><author><name sortKey="Lu, H Z" sort="Lu, H Z" uniqKey="Lu H" first="H Z" last="Lu">H Z Lu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508</wicri:regionArea><wicri:noRegion>Shanghai 201508</wicri:noRegion></affiliation></author></analytic><series><title level="j">Zhonghua nei ke za zhi</title><idno type="ISSN">0578-1426</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Angiotensin Receptor Antagonists (MeSH)</term><term>Angiotensin-Converting Enzyme Inhibitors (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>China (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Humans (MeSH)</term><term>Hypertension (complications)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Retrospective Studies (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Antagonistes des récepteurs aux angiotensines (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>Chine (MeSH)</term><term>Humains (MeSH)</term><term>Hypertension artérielle (complications)</term><term>Infections à coronavirus (complications)</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (complications)</term><term>Sujet âgé (MeSH)</term><term>Études rétrospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Angiotensin Receptor Antagonists</term><term>Angiotensin-Converting Enzyme Inhibitors</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>China</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Hypertension</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Betacoronavirus</term><term>Humans</term><term>Middle Aged</term><term>Pandemics</term><term>Retrospective Studies</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Antagonistes des récepteurs aux angiotensines</term><term>Betacoronavirus</term><term>Chine</term><term>Humains</term><term>Hypertension artérielle</term><term>Infections à coronavirus</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term><term>Pandémies</term><term>Pneumopathie virale</term><term>Sujet âgé</term><term>Études rétrospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>République populaire de Chine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><b>Objective:</b> To analyze the effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) on coronavirus disease 2019 (COVID-19) patients with hypertension, and to provide an evidence for selecting antihypertensive drugs in those patients. <b>Methods:</b> Clinical data were retrospectively analyzed in 58 COVID-19 patients with hypertension admitted to Shanghai Public Health Clinical Center from January 20 to February 22, 2020, including epidemiological history, clinical manifestations, laboratory findings, chest CT and outcome. Patients were divided into ACEI/ARB group and non-ACEI/ARB group. <b>Results:</b> Twenty-six patients were in ACEI/ARB group and the other 32 patients in non-ACEI/ARB group, with median age 64.0 (49.5, 72.0) years and 64.0 (57.0, 68.8) years respectively. The median time to onset was 5(3, 8) days in ACEI/ARB group and 4 (3, 7) days in non-ACEI/ARB group, the proportion of patients with severe or critical illness was 19.2% and 15.6% respectively. The main clinical symptoms in two groups were fever (80.8% vs. 84.4%) and cough (23.1% vs. 31.3%). The following parameters were comparable including lymphocyte counts, C-reactive protein, lactate dehydrogenase, D-dimer, bilateral involvement in chest CT (76.9% vs. 71.9%), worsening of COVID-19 (15.4% vs. 9.4%), favorable outcome (92.3% vs. 96.9%) between ACEI/ARB group and non-ACEI/ARB group respectively (all <i>P></i>0.05). However, compared with non-ACEI/ARB group, serum creatinine [80.49 (68.72, 95.30) μmol/L vs. 71.29 (50.98, 76.98) μmol/L, <i>P=</i>0.007] was higher significantly in ACEI/ARB group. <b>Conclusions:</b> ACEI/ARB drugs have no significant effects on baseline clinical parameters (serum creatine and myoglobin excluded) , outcome, and prognosis of COVID-19 patients with hypertension. Antihypertensive drugs are not suggested to adjust in those patients, but the potential impairment of renal function as elevation of serum creatinine should be paid attention in patients administrating ACEI/ARB drugs.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32838499</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0578-1426</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Zhonghua nei ke za zhi</Title><ISOAbbreviation>Zhonghua Nei Ke Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].</ArticleTitle><Pagination><MedlinePgn>689-694</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112138-20200229-00155</ELocationID><Abstract><AbstractText><b>Objective:</b> To analyze the effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) on coronavirus disease 2019 (COVID-19) patients with hypertension, and to provide an evidence for selecting antihypertensive drugs in those patients. <b>Methods:</b> Clinical data were retrospectively analyzed in 58 COVID-19 patients with hypertension admitted to Shanghai Public Health Clinical Center from January 20 to February 22, 2020, including epidemiological history, clinical manifestations, laboratory findings, chest CT and outcome. Patients were divided into ACEI/ARB group and non-ACEI/ARB group. <b>Results:</b> Twenty-six patients were in ACEI/ARB group and the other 32 patients in non-ACEI/ARB group, with median age 64.0 (49.5, 72.0) years and 64.0 (57.0, 68.8) years respectively. The median time to onset was 5(3, 8) days in ACEI/ARB group and 4 (3, 7) days in non-ACEI/ARB group, the proportion of patients with severe or critical illness was 19.2% and 15.6% respectively. The main clinical symptoms in two groups were fever (80.8% vs. 84.4%) and cough (23.1% vs. 31.3%). The following parameters were comparable including lymphocyte counts, C-reactive protein, lactate dehydrogenase, D-dimer, bilateral involvement in chest CT (76.9% vs. 71.9%), worsening of COVID-19 (15.4% vs. 9.4%), favorable outcome (92.3% vs. 96.9%) between ACEI/ARB group and non-ACEI/ARB group respectively (all <i>P></i>0.05). However, compared with non-ACEI/ARB group, serum creatinine [80.49 (68.72, 95.30) μmol/L vs. 71.29 (50.98, 76.98) μmol/L, <i>P=</i>0.007] was higher significantly in ACEI/ARB group. <b>Conclusions:</b> ACEI/ARB drugs have no significant effects on baseline clinical parameters (serum creatine and myoglobin excluded) , outcome, and prognosis of COVID-19 patients with hypertension. Antihypertensive drugs are not suggested to adjust in those patients, but the potential impairment of renal function as elevation of serum creatinine should be paid attention in patients administrating ACEI/ARB drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Deparment of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Z P</ForeName><Initials>ZP</Initials><AffiliationInfo><Affiliation>Department of Severe Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Y Y</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Department of Severe Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>S B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>X H</ForeName><Initials>XH</Initials><AffiliationInfo><Affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>S H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Tuberculosis, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>H Z</ForeName><Initials>HZ</Initials><AffiliationInfo><Affiliation>Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><GrantList CompleteYN="Y"><Grant><GrantID>IDF162005</GrantID><Agency>Top University and First-class Discipline Construction Project of Fudan University</Agency><Country></Country></Grant><Grant><GrantID>2020YJKY01</GrantID><Agency>Scientific Research Project for Novel Coronavirus "2019-nCoV" of Shanghai Public Health Clinical Center</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Nei Ke Za Zhi</MedlineTA><NlmUniqueID>16210490R</NlmUniqueID><ISSNLinking>0578-1426</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>目的：</b> 分析血管紧张素转换酶抑制剂/血管紧张素受体Ⅱ拮抗剂（ACEI/ARB）对新型冠状病毒肺炎（COVID-19）患者临床特征的影响，为COVID-19合并高血压患者降压药物的选择提供依据。 <b>方法：</b> 收集2020年1月20日至2月22日上海市公共卫生临床中心58例COVID-19合并高血压患者的临床资料。根据服用抗高血压药物的情况，将患者分为ACEI/ARB组和非ACEI/ARB组，比较两组流行病学、临床表现、实验室及影像学表现，病程转归及预后的差异。 <b>结果：</b> ACEI/ARB组患者26例，非ACEI/ARB组32例；两组中位年龄[64.0（49.5，72）岁比64.0（57.0，68.8）岁]、发病时间[5（3，8）d比4（3，7）d]、入院时重症/危重症比例（19.2%比15.6%）、病情恶化（15.4%比9.4%）和好转出院（92.3%比96.9%）差异无统计学意义（<i>P</i>值均>0.05）；两组患者症状均以发热、咳嗽为主，两组均存在淋巴细胞计数低，C反应蛋白高，乳酸脱氢酶及D-二聚体大部分正常，胸部CT以双侧受累为主。与非ACEI/ARB组相比，ACEI/ARB组肌酐较高[80.49（68.72，95.30）μmol/L比71.29（50.98，76.98）μmol/L，<i>P=</i>0.007]，差异有统计学意义。 <b>结论：</b> ACEI/ARB对COVID-19合并高血压患者的临床基线（肌酐、肌红蛋白除外）、转归及预后无明显影响，这类患者在入院时降压药物暂可不用调整，但ACEI/ARB潜在、功能性的升高血肌酐需要引起临床医生关注。.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiotensin converting enzyme inhibitor</Keyword><Keyword MajorTopicYN="N">Angiotensin Ⅱ receptor antagonist</Keyword><Keyword MajorTopicYN="N">Clinical characteristics</Keyword><Keyword MajorTopicYN="N">Coronavirus disease 2019</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32838499</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn112138-20200229-00155</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Huang, W" sort="Huang, W" uniqKey="Huang W" first="W" last="Huang">W. Huang</name></noRegion><name sortKey="Huang, D" sort="Huang, D" uniqKey="Huang D" first="D" last="Huang">D. Huang</name><name sortKey="Li, T" sort="Li, T" uniqKey="Li T" first="T" last="Li">T. Li</name><name sortKey="Ling, Y" sort="Ling, Y" uniqKey="Ling Y" first="Y" last="Ling">Y. Ling</name><name sortKey="Liu, X H" sort="Liu, X H" uniqKey="Liu X" first="X H" last="Liu">X H Liu</name><name sortKey="Lu, H Z" sort="Lu, H Z" uniqKey="Lu H" first="H Z" last="Lu">H Z Lu</name><name sortKey="Lu, S H" sort="Lu, S H" uniqKey="Lu S" first="S H" last="Lu">S H Lu</name><name sortKey="Qian, Z P" sort="Qian, Z P" uniqKey="Qian Z" first="Z P" last="Qian">Z P Qian</name><name sortKey="Xia, L" sort="Xia, L" uniqKey="Xia L" first="L" last="Xia">L. Xia</name><name sortKey="Xu, S B" sort="Xu, S B" uniqKey="Xu S" first="S B" last="Xu">S B Xu</name><name sortKey="Yang, Y" sort="Yang, Y" uniqKey="Yang Y" first="Y" last="Yang">Y. Yang</name><name sortKey="Zhang, Y Y" sort="Zhang, Y Y" uniqKey="Zhang Y" first="Y Y" last="Zhang">Y Y Zhang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000056 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000056 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32838499
|texte= [Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32838499" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |